Natural killer (NK) cells were first identified for their ability to kill tumor cells without activation. NK cells are a focus of many cancer immunotherapies, as they display rapid and potent immunity to metastasis or hematological cancers.
Measuring the activity of natural killer cells is necessary for many immune applications. ATCC’s Human Primary CD56+ NK Cells
provide researchers with a physiologically relevant and highly validated source of natural killer cells for cytotoxic killing activity assays. Combined with ATCC’s K-562-GFP
cells, scientists can perform cytotoxicity assays with no upstream preparation in a manner which addresses the drawbacks of previous methods.
Cytotoxic Killing Activity in ATCC Natural Killer Cells
Three lots of human natural killer cells (ATCC® PCS-800-019™) were tested for cytotoxic killing activity using GFP-expressing K-562 cells in a flow cytometry-based assay. Depending on the effector:target ratio and the donor, the extent of lysis ranged from 4% to a maximum of 54%.
NATURAL KILLER TARGET CELLS
Cancer Immunology Resources